This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Educational Foundation Kyushu Bunka Gakuen, Kaneka Corporation, National University Corporation Kumamoto University. Active years: 2026.
Company Filing History:
1 out of 2 
1 out of 1,768 
1 out of 9 Years Active: 2026
Title: Teruaki Masuda: Innovator in Transthyretin Amyloidosis Treatment
Introduction
Teruaki Masuda is a notable inventor based in Kumamoto, Japan. He has made significant contributions to the field of medicine, particularly in the treatment of transthyretin amyloidosis. His innovative work has led to the development of a unique stabilizing agent that holds promise for patients suffering from this condition.
Latest Patents
Masuda holds a patent for a transthyretin tetramer stabilizing agent, which serves as a preventing agent or progression suppressing agent for transthyretin amyloidosis. This invention includes glabridin, glabrene, and glabrol as key components. The patent aims to provide a solution for stabilizing the transthyretin tetramer, thereby offering a potential therapeutic approach to managing transthyretin amyloidosis. He has 1 patent to his name.
Career Highlights
Throughout his career, Masuda has been associated with reputable institutions such as the Educational Foundation Kyushu Bunka Gakuen and the National University Corporation Kumamoto University. His work in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Masuda has collaborated with esteemed colleagues, including Hiroaki Matsushita and Jinko Sawashita. These partnerships have facilitated the exchange of ideas and fostered innovation in their respective fields.
Conclusion
Teruaki Masuda's contributions to the treatment of transthyretin amyloidosis through his innovative patent highlight his role as a significant inventor in the medical field. His work continues to inspire advancements in therapeutic solutions for patients.